Mechanistically, our study revealed that the key innate immune-regulatory gene IKBKE was uniquely downregulated in cancer cells compared with normal cells in primary prostate cancers of patients in TCGA, but not in the 16 other cancer types examined, implying that the IKKε-mediated innate immune response, including IFN signaling and expression of antigen presentation machinery genes, was compromised in hormone-naive prostate cancer. The gene discussed is IFNA1; the disease is cancer.